{"id":"3443e0eabad8","type":"article","url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","title":"2021 ACC HF-behandeloptimalisatie update: antwoorden op 10 cruciale vragen","title_en":"2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.11.022","source_url":"https://doi.org/10.1016/j.jacc.2020.11.022","authors":["Thomas M Maddox","James L Januzzi","Larry A Allen","Khadijah Breathett","Javed Butler","Leslie L Davis","Gregg C Fonarow","Nasrien E Ibrahim","JoAnn Lindenfeld","Frederick A Masoudi","Shweta R Motiwala","Estefania Oliveros","J Herbert Patterson","Mary Norine Walsh","Alan Wasserman","Clyde W Yancy","Quentin R Youmans"],"significance":9,"published":"2021-02-16","source_date":"2021-02-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"The 2021 ACC Expert Consensus update addressed 10 pivotal questions on heart failure treatment optimization, integrating evidence for SGLT2 inhibitors across the ejection fraction spectrum, vericiguat in recently decompensated HFrEF, and practical implementation of quadruple therapy.","created":"2026-07-03T10:29:04Z","updated":"2026-07-03T13:28:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"ACC 2021 update van de HF-behandeloptimalisatie pathway met antwoorden op 10 cruciale vragen over SGLT2-remmers, vericiguat, en implementatie van quadruple therapie.","abstract_original":""}